Clinicians in low- and middle-income countries (LMICs) face significant hurdles in managing drug-resistant epilepsy (DRE). While surgery offers a potential cure, outcomes remain highly variable. Consequently, researchers are investigating how genetic biomarker epilepsy screening can improve patient selection and treatment outcomes. Integrating these tests into presurgical protocols may bridge the treatment gap in resource-constrained environments like India.

Clinical Utility of Genetic Biomarker Epilepsy Screening

Current surgical success rates for DRE fluctuate between 30% and 70%. This wide range highlights the need for more precise diagnostic tools. Genetic stratification identifies specific mutations that correlate with poor or favorable surgical outcomes. For instance, mutations in the ABCB1 gene or specific SCN1A variants can influence how a patient responds to interventions. Furthermore, identifying structural abnormalities helps surgeons localize seizure foci more accurately. Therefore, genetic data allows for personalized treatment pathways that maximize recovery chances.

Cost-Effectiveness in LMIC Settings

Resource limitations in LMICs necessitate the efficient use of healthcare funds. Implementing genetic testing might seem expensive initially. However, it significantly enhances long-term cost-effectiveness. By predicting which patients are unlikely to benefit from surgery, clinicians avoid unnecessary and costly interventions. Moreover, precision neurology reduces the burden on healthcare systems by streamlining the diagnostic process. Ultimately, these tools support the development of more sustainable epilepsy management strategies.

Challenges and Future Directions

Transitioning to a precision medicine model requires building local research capacity. Many LMICs currently lack the infrastructure for advanced genomic sequencing. Nevertheless, global collaborations are helping to lower these barriers. In addition, local guidelines must evolve to incorporate genetic stratification. As evidence grows, genetic testing will likely become a cornerstone of routine presurgical evaluations. This shift promises a more equitable future for patients with complex epilepsy worldwide.

FAQs

How does genetic testing improve epilepsy surgery?

Genetic testing helps identify specific mutations that predict a patient's response to surgery. This allows clinicians to select candidates more effectively and avoid procedures that are unlikely to stop seizures.

Which genes are most relevant in drug-resistant epilepsy?

Research highlights several key genes, including ABCB1, SCN1A, and CNIH3. These genes often influence drug metabolism or the structural integrity of neural pathways involved in seizure generation.

Is genetic screening feasible in low-resource settings?

While infrastructure remains a challenge, genetic screening is increasingly cost-effective. It helps avoid unnecessary surgical costs and supports personalized medicine, which reduces the overall burden on the healthcare system.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider regarding any medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Kalinina D et al. Genetic biomarker screening for drug-resistant epilepsy in low- and middle-income countries (LMICs). Adv Clin Exp Med. 2026 May 20. doi: 10.17219/acem/209664. PMID: 42160116.

Fabbri L, et al. Spikes on ripples are better interictal biomarkers of epilepsy than spikes or ripples. Brain Communications. 2025.

Sisodiya S, et al. Common genetic variants linked to drug-resistant epilepsy. eBioMedicine. 2025.